ClinicalTrials.gg
CompletedNCT00804856Updated Oct 3, 2023Results posted

Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

A Phase 2 interventional study of Volasertib and Cytarabine in Leukemia, Myeloid, Acute, sponsored by Boehringer Ingelheim. Completed at 27 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Enrollment
35th of 239
180 · median 48
Started
2008
with 8 others
Phase 2
112 of 247
21 open now
Registered
76th of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 35th largest by enrollment of the 239 interventional ones that give a count, is one of 9 that started in 2008, is one of 112 in phase 2, and was the 76th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The trial will be performed in two parts, a phase I part and a phase IIa part. In the phase I part of the trial, BI 6727 will be investigated as monotherapy and in combination with low dose cytarabine (LD-Ara-C) in patients with relapsed/refractory AML that are not eligible for intensive treatment. The dose of BI 6727 will be escalated to determine the maximum tolerated dose (MTD) of BI 6727 monotherapy and BI 6727 in combination with LD-Ara-C in AML patients. In the phase IIa part, the combination of BI 6727 at MTD with LD-Ara-C and LD-Ara-C monotherapy will be investigated to explore the efficacy of the combination schedule in comparison to LD-Ara-C monotherapy in previously untreated AML patients that are not eligible for intensive treatment.

03

Conditions studied

  • Leukemia, Myeloid, Acute
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female adult with AML ineligible for intensive treatment (phase I part only) Male or female adult with previously untreated AML ineligible for intensive treatment (phase IIa part only) Confirmed diagnosis of AML according to the WHO definition (except for acute promyelocytic leukaemia, APL) Patient is eligible for LD-Ara-C treatment > 3 months Eastern co-operative oncology group (, R01-0787) performance score \<=2 at screening Signed written consistent with international conference on harmonisation, good clinical practice (ICH-GCP) and local legislation

Exclusion criteria

Exclusion criteria:

Previously untreated AML (phase I part only) or treatment refractory AML (phase IIa part only) Patient with APL (AML subtype M3 according to the French-American-British (FAB) classification) to one of the trial drugs or the Other requiring treatment Symptomatic central nervous system involvement (e.g. long QT syndrome, QTcF>470 ms) Aspartate amino transferase () or alanine amino transferase (ALT) greater than 2.5 times the (ULN), or AST or ALT greater than 5 times the ULN in case of known leukaemia liver involvement (PT) > 1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin) greater than 1.5 mg/dl (> 26 mcmol/L) Serum creatinine greater than 2.0 mg/dl Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris, cardiac arrhythmia or severe heart failure/cardiac insufficiency.

Psychiatric illness or social situation that would limit compliance with trial requirements Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug for cytarabine treatment according to the SPC Female patients of who are sexually active and unwilling to use a medically acceptable method of during the trial, i.e. combination of two forms of effective contraception (hormonal contraception, intrauterine device, condom with spermicide, etc.).

Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial Pregnant or nursing female patients Patient unable to comply with the protocol

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Phase I Schedule A. Volasertib 150 mg+LDAC

    Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

    Drug: Volasertib · Drug: Cytarabine

  • Experimental
    Phase I Schedule A. Volasertib 200 mg+LDAC

    Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

    Drug: Volasertib · Drug: Cytarabine

  • Experimental
    Phase I Schedule A. Volasertib 250 mg+LDAC

    Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

    Drug: Volasertib · Drug: Cytarabine

  • Experimental
    Phase I Schedule A. Volasertib 300 mg+LDAC

    Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

    Drug: Volasertib · Drug: Cytarabine

  • Experimental
    Phase I Schedule A. Volasertib 350 mg+LDAC

    Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

    Drug: Volasertib · Drug: Cytarabine

  • Experimental
    Phase I Schedule A. Volasertib 400 mg+LDAC

    Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

    Drug: Volasertib · Drug: Cytarabine

  • Experimental
    Phase I Schedule B. Volasertib 150 mg

    Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

    Drug: Volasertib

  • Experimental
    Phase I Schedule B. Volasertib 200 mg

    Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

    Drug: Volasertib

  • Experimental
    Phase I Schedule B. Volasertib 350 mg

    Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

    Drug: Volasertib

  • Experimental
    Phase I Schedule B. Volasertib 400 mg

    Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

    Drug: Volasertib

  • Experimental
    Phase I Schedule B. Volasertib 450 mg

    Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

    Drug: Volasertib

  • Experimental
    Phase I Schedule B. Volasertib 500 mg

    Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

    Drug: Volasertib

  • Experimental
    Phase I Schedule B. Volasertib 550 mg

    Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

    Drug: Volasertib

  • Active comparator
    Phase II Schedule C. LDAC

    Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.

    Drug: Cytarabine

  • Experimental
    Phase II Schedule A. Volasertib 350 mg+LDAC

    Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.

    Drug: Volasertib · Drug: Cytarabine

Interventions

  • Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

  • Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B)

    To determine the Maximum tolerated dose (MTD), dose escalation was conducted following the 3+3 design with de-escalation. The MTD was defined as the highest dose at which 6 patients had been treated and less than 2 patients experienced a Dose limiting toxicity (DLT) within the first cycle of treatment. The MTD was defined based on safety data from the first cycle only. DLT is defined as drug related Common terminology criteria for adverse events (CTCAE) grade ≥ 3 nonhaematological toxicity (excluding: untreated nausea, untreated vomiting, CTCAE grade 3 untreated diarrhoea, CTCAE grade 3 "febrile neutropenia" and CTCAE grade 3 "infection with grade 3 or 4 neutrophils"). In patients with complete remission with incomplete blood count recovery (CRi) or partial remission (PR), persistent CTCAE grade 4 neutropenia or thrombocytopenia until three weeks after the end of the treatment cycle will be regarded a DLT.

    Time frame: First Treatment cycle, up to 28 days.

  2. Phase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))

    Phase II: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.

    Time frame: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.

  3. Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)

    A DLT was defined as a drug related CTCAE (Common Toxicity Criteria for Adverse Events) Grade ≥3 non-haematological toxicity (excluding untreated nausea, untreated vomiting, Grade 3 untreated diarrhea, Grade 3 febrile neutropenia, and Grade 3 infection with Grade 3 or 4 neutrophils). In patients with CRi (Complete Remission with Incomplete Blood Count Recovery) or PR (Partial Remission), persistent Grade 4 neutropenia or thrombocytopenia for 3 weeks after the end of the treatment cycle was regarded as a DLT unless the respective Grade 4 cytopenia was preexistent. In patients who required platelet substitution to maintain a Grade \<4 before treatment, a Grade 4 thrombocytopenia after treatment did not constitute a DLT.

    Time frame: First Treatment cycle, up to 28 days.

Secondary outcomes

  1. Best Overall Response

    * CR * CR+CRi * Partial remission: CR except bone marrow (BM) contained ≥5% but \<25% blasts (or ≤50% initial blasts), or \<5% blasts in presence of Auer rods or abnormal morphology. * No change: survived ≥7 days (d) after 1st cycle with persistent leukemia in last peripheral blood smear or BM, or with persistent extramedullary disease, without further deterioration due to leukemia or increase of blasts in BM or peripheral blood. * Aplasia: survived ≥7d after 1st cycle, died whilst cytopenic, with last post-treatment BM result aplastic or hypoplastic and without leukemia blasts. * Indeterminate: survived \<7 d after 1st cycle or survived ≥7d after 1st cycle, died with no persistent leukemia in peripheral smear but no post-treatment BM examination or did not complete 1st cycle. * Progressive disease: survived ≥7d after 1st cycle with increase of blast population in BM or peripheral blood or aggravation or new extramedullary disease or further deterioration or death due to leukemia.

    Time frame: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.

  2. Phase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi)

    Phase I: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.

    Time frame: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 594 days.

  3. Phase II: Event Free Survival

    Event-free survival (EFS) \[days\] was the shortest duration of the following: (a) Date of assessment indicating PD on the response page of the eCRF (Electronic Case Report Form) - date of randomisation + 1 day (b) Date of assessment indicating clinical progressive disease (PD) on the disease or responses pages of the of eCRF- date of randomisation + 1 day (c) Date of assessment indicating PD on the patient status page of the eCRF - date of randomisation +1 day (for patients who had not been censored before this time point) (d) Death date - date of randomisation +1 day Patients not being assessed PD, clinical PD, or death during the trial were censored. EFS was analysed with the Kaplan-Meier method for each of the treatment arms.

    Time frame: The patients that entered the trial, and measured from the date of randomization to the date of disease progression (treatment failure), relapse or death from any cause, whichever occurred first, up to 1000 days..

  4. Phase II: Overall Survival

    Overall survival \[days\] = (date of death - date of randomisation + 1 day), for patients with known date of death. Overall survival (censored) \[days\] = (date of last trial visit or follow-up - date of randomisation + 1 day), for patients who were still alive at time of database lock. Overall survival (OS) was analysed with the Kaplan-Meier method for each of the treatment arms.

    Time frame: The patients that entered the trial, and measured from the date of randomisation until death from any cause, up to 1100 days..

  5. Phase II: Relapse - Free Survival

    Relapse-free survival \[days\] = (date of first recurrence of disease or death after entering the trial - date of first occurrence of CR or CRi after entering the trial+ 1 day) for patients with a recurrence (this value should be positive). Relapse-free survival (censored) \[days\] = (date of last trial visit or follow-up - date of first occurrence of CR or CRi after entering the trial + 1 day) for patients who did not experience recurrence of disease or death at the time of analysis.

    Time frame: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence or death from any cause, whichever occurred first, up to 900 days.

  6. Phase II: Remission Duration

    Remission duration analysis was defined only for patients who achieved Complete remission (CR) or Complete remission with incomplete blood count recovery (CRi), and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of cause.

    Time frame: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 900 days.

  7. Phase II: Time to Remission

    Time to remission \[days\] = (date of first occurrence of CR or CRi after entering the trial-date of randomisation + 1 day) for patients with an objective response.

    Time frame: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 158 days.

  8. Best Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment

    ECOG performance score change from baseline to last visit of last cycle = ECOG performance score at last visit of the last cycle - ECOG performance score at baseline. ECOG performance score changes from baseline were also categorised on a 3-point categorical scale: deteriorated (-1), unchanged (0), and improved (1). The number of participants for category of ECOG score change is reported.

    Time frame: Baseline and End of Treatment (up to 869 days).

  9. Total Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib

    Total Clearance (CL) of Volasertib in Plasma after Intravenous (i.v.) Administration of Volasertib.

    Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.

  10. Apparent Volume of Distribution of Volasertib at Steady State (VSS)

    Apparent Volume of Distribution of volasertib at steady state (VSS) following Intravenous (i.v.) administration.

    Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.

  11. Dose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm)

    Cmax, norm: Maximum measured concentration of Cytarabine in plasma. The dose normalisation was done by dividing by the dose applied. Unit: nanogram/milliliter/milligram: ((ng/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.

    Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.

  12. Dose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours

    AUC0-4,norm: Area under the concentration-time curve of Cytarabine in plasma over the time interval from zero extrapolated to 4 hours. The dose normalisation was done by dividing by dose applied. Unit: nanogram\*hour/milliliter/milligram: ((ng\*h/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.

    Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h after first drug administration.

  13. Absolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals

    ECG (Electro Cardio Gram) Measurements: Absolute QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) Corrected for Heart Rate Using Fridericia's Formula) Intervals. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.

    Time frame: Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.

  14. QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Change From Baseline at Cycle 1

    ECG Measurements: QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) changes from baseline at each time point: The QTcF post baseline measurement obtained at time t minus baseline QTcF measurement. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.

    Time frame: Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.

  15. Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1

    Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

    Time frame: First treatment cycle, up to 28 days.

  16. Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1

    Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

    Time frame: First treatment cycle, up to 28 days.

  17. Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles

    Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

    Time frame: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 615 days.

  18. Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles

    Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

    Time frame: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 597 days.

  19. Phase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles

    Number of patients with AEs following in the in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

    Time frame: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 890 days.

07

Results

Posted Oct 3, 2023

Participant flow

Open-label, randomized, dose escalation study. In this trial 180 patients were entered and randomised. However 3 patients were entered but not treated in Phase I and 2 patients were not treated in Phase II. Thus total 175 patients were treated in this trial.

Participant flow — Overall Study
MilestonePhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Started4359831125623544542
Completed000000000000000
Not completed4359831125623544542
Withdrew: Progressive disease324641824512222620
Withdrew: Dose limiting toxicity (dlt)000010000000001
Withdrew: Other adverse event1112213001520613
Withdrew: Non compliance with protocol000000000000020
Withdrew: Refused to continue medication000110000030115
Withdrew: Other reason than listed above0000010010311103

Outcome measures

PrimaryPhase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B)

To determine the Maximum tolerated dose (MTD), dose escalation was conducted following the 3+3 design with de-escalation. The MTD was defined as the highest dose at which 6 patients had been treated and less than 2 patients experienced a Dose limiting toxicity (DLT) within the first cycle of treatment. The MTD was defined based on safety data from the first cycle only. DLT is defined as drug related Common terminology criteria for adverse events (CTCAE) grade ≥ 3 nonhaematological toxicity (excluding: untreated nausea, untreated vomiting, CTCAE grade 3 untreated diarrhoea, CTCAE grade 3 "febrile neutropenia" and CTCAE grade 3 "infection with grade 3 or 4 neutrophils"). In patients with complete remission with incomplete blood count recovery (CRi) or partial remission (PR), persistent CTCAE grade 4 neutropenia or thrombocytopenia until three weeks after the end of the treatment cycle will be regarded a DLT.

Time frame:
First Treatment cycle, up to 28 days.
Reported as:
Number · milligram (mg)
Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B)
milligram (mg)Phase I Schedule A. Volasertib+LDACPhase I Schedule B. Volasertib
Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B)350450
PrimaryPhase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))

Phase II: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.

Time frame:
The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.
Reported as:
Count of participants · Participants
Phase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))
ParticipantsPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Phase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))613
Statistical analysis
  • Phase II Schedule C. LDAC vs Phase II Schedule A. Volasertib 350 mg+LDAC · Regression, Logistic · p = 0.0523 · Odds ratio (or): 2.91 · 95% CI 0.99 to 8.58Ratio calculated as Phase II Schedule A Volasertib 350mg+LDAC divided by Phase II Schedule C LDAC.
PrimaryPhase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)

A DLT was defined as a drug related CTCAE (Common Toxicity Criteria for Adverse Events) Grade ≥3 non-haematological toxicity (excluding untreated nausea, untreated vomiting, Grade 3 untreated diarrhea, Grade 3 febrile neutropenia, and Grade 3 infection with Grade 3 or 4 neutrophils). In patients with CRi (Complete Remission with Incomplete Blood Count Recovery) or PR (Partial Remission), persistent Grade 4 neutropenia or thrombocytopenia for 3 weeks after the end of the treatment cycle was regarded as a DLT unless the respective Grade 4 cytopenia was preexistent. In patients who required platelet substitution to maintain a Grade \<4 before treatment, a Grade 4 thrombocytopenia after treatment did not constitute a DLT.

Time frame:
First Treatment cycle, up to 28 days.
Reported as:
Count of participants · Participants
Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
ParticipantsPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACTotal Phase I Combined. Schedule A.Phase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgTotal Phase I Combined. Schedule B.
Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)000112410011227
SecondaryBest Overall Response

* CR * CR+CRi * Partial remission: CR except bone marrow (BM) contained ≥5% but \<25% blasts (or ≤50% initial blasts), or \<5% blasts in presence of Auer rods or abnormal morphology. * No change: survived ≥7 days (d) after 1st cycle with persistent leukemia in last peripheral blood smear or BM, or with persistent extramedullary disease, without further deterioration due to leukemia or increase of blasts in BM or peripheral blood. * Aplasia: survived ≥7d after 1st cycle, died whilst cytopenic, with last post-treatment BM result aplastic or hypoplastic and without leukemia blasts. * Indeterminate: survived \<7 d after 1st cycle or survived ≥7d after 1st cycle, died with no persistent leukemia in peripheral smear but no post-treatment BM examination or did not complete 1st cycle. * Progressive disease: survived ≥7d after 1st cycle with increase of blast population in BM or peripheral blood or aggravation or new extramedullary disease or further deterioration or death due to leukemia.

Time frame:
The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.
Reported as:
Count of participants · Participants
Best Overall Response
ParticipantsPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACTotal Phase I Combined. Schedule A.Phase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgTotal Phase I Combined. Schedule B.Phase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDACTotal Phase II Combined. Schedule A and C.
Complete remission002000200000000369
CRi0201104001220053710
Partial remission000000000102014224
No change2121118402273018181533
Aplasia000000000013116000
Indeterminate000231610000001358
Progressive disease2013311062117111914721
Not evaluable000100100002013202
Missing000100100000000000
SecondaryPhase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi)

Phase I: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.

Time frame:
The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 594 days.
Reported as:
Count of participants · Participants
Phase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi)
ParticipantsPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACTotal Phase I Combined. Schedule A.Phase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgTotal Phase I Combined. Schedule B.
Phase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi)022110600122005
SecondaryPhase II: Event Free Survival

Event-free survival (EFS) \[days\] was the shortest duration of the following: (a) Date of assessment indicating PD on the response page of the eCRF (Electronic Case Report Form) - date of randomisation + 1 day (b) Date of assessment indicating clinical progressive disease (PD) on the disease or responses pages of the of eCRF- date of randomisation + 1 day (c) Date of assessment indicating PD on the patient status page of the eCRF - date of randomisation +1 day (for patients who had not been censored before this time point) (d) Death date - date of randomisation +1 day Patients not being assessed PD, clinical PD, or death during the trial were censored. EFS was analysed with the Kaplan-Meier method for each of the treatment arms.

Time frame:
The patients that entered the trial, and measured from the date of randomization to the date of disease progression (treatment failure), relapse or death from any cause, whichever occurred first, up to 1000 days..
Reported as:
Median · Days
Phase II: Event Free Survival
DaysPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Phase II: Event Free Survival69.0 (27 to 215)169.0 (39 to 470)
Statistical analysis
  • Phase II Schedule C. LDAC vs Phase II Schedule A. Volasertib 350 mg+LDAC · Log Rank · p = 0.0208 · Hazard ratio (hr): 0.57 · 95% CI 0.35 to 0.92Ratio calculated as Phase II Schedule A Volasertib 350mg+LDAC divided by Phase II Schedule C LDAC.
SecondaryPhase II: Overall Survival

Overall survival \[days\] = (date of death - date of randomisation + 1 day), for patients with known date of death. Overall survival (censored) \[days\] = (date of last trial visit or follow-up - date of randomisation + 1 day), for patients who were still alive at time of database lock. Overall survival (OS) was analysed with the Kaplan-Meier method for each of the treatment arms.

Time frame:
The patients that entered the trial, and measured from the date of randomisation until death from any cause, up to 1100 days..
Reported as:
Median · Days
Phase II: Overall Survival
DaysPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Phase II: Overall Survival158.0 (78 to 347)245.0 (73 to 689)
Statistical analysis
  • Phase II Schedule C. LDAC vs Phase II Schedule A. Volasertib 350 mg+LDAC · Log Rank · p = 0.0465 · Hazard ratio (hr): 0.63 · 95% CI 0.40 to 1.00Ratio calculated as Phase II Schedule A Volasertib 350mg+LDAC divided by Phase II Schedule C LDAC.
SecondaryPhase II: Relapse - Free Survival

Relapse-free survival \[days\] = (date of first recurrence of disease or death after entering the trial - date of first occurrence of CR or CRi after entering the trial+ 1 day) for patients with a recurrence (this value should be positive). Relapse-free survival (censored) \[days\] = (date of last trial visit or follow-up - date of first occurrence of CR or CRi after entering the trial + 1 day) for patients who did not experience recurrence of disease or death at the time of analysis.

Time frame:
The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence or death from any cause, whichever occurred first, up to 900 days.
Reported as:
Median · Days
Phase II: Relapse - Free Survival
DaysPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Phase II: Relapse - Free Survival304.0 (113 to 367)563.0 (427 to NA)
SecondaryPhase II: Remission Duration

Remission duration analysis was defined only for patients who achieved Complete remission (CR) or Complete remission with incomplete blood count recovery (CRi), and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of cause.

Time frame:
The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 900 days.
Reported as:
Median · Days
Phase II: Remission Duration
DaysPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Phase II: Remission Duration367.0 (113 to 367)687.0 (427 to NA)
SecondaryPhase II: Time to Remission

Time to remission \[days\] = (date of first occurrence of CR or CRi after entering the trial-date of randomisation + 1 day) for patients with an objective response.

Time frame:
The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 158 days.
Reported as:
Median · Days
Phase II: Time to Remission
DaysPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Phase II: Time to Remission63.5 (30 to 125)71.0 (29 to 158)
SecondaryBest Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment

ECOG performance score change from baseline to last visit of last cycle = ECOG performance score at last visit of the last cycle - ECOG performance score at baseline. ECOG performance score changes from baseline were also categorised on a 3-point categorical scale: deteriorated (-1), unchanged (0), and improved (1). The number of participants for category of ECOG score change is reported.

Time frame:
Baseline and End of Treatment (up to 869 days).
Reported as:
Count of participants · Participants
Best Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment
ParticipantsPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACTotal Phase I Combined. Schedule A.Phase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgTotal Phase I Comined. Schedule B.Phase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDACTotal Phase II. Schedule A and C.
Unchanged315251179104142333221537
Improved02010030011310681321
Deteriorated1002317114152014121123
SecondaryTotal Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib

Total Clearance (CL) of Volasertib in Plasma after Intravenous (i.v.) Administration of Volasertib.

Time frame:
Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.
Reported as:
Geometric mean · millilitre/minute (mL/min)
Total Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib
millilitre/minute (mL/min)Phase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgPhase II Schedule A. Volasertib 350 mg+LDAC.
Total Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib1280 ± 52.8972 ± 26.6864 ± 27.61150 ± 34.41000 ± 36.2852 ± 49.61330 ± 29.3NA ± NA810 ± 35.11120 ± 62.1920 ± 36.21140 ± 38.5939 ± 93.2897 ± 42.8
SecondaryApparent Volume of Distribution of Volasertib at Steady State (VSS)

Apparent Volume of Distribution of volasertib at steady state (VSS) following Intravenous (i.v.) administration.

Time frame:
Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.
Reported as:
Geometric mean · Liter (L)
Apparent Volume of Distribution of Volasertib at Steady State (VSS)
Liter (L)Phase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgPhase II Schedule A. Volasertib 350 mg+LDAC.
Apparent Volume of Distribution of Volasertib at Steady State (VSS)10600 ± 111.08640 ± 14.17000 ± 26.66320 ± 35.95270 ± 58.24830 ± 56.710300 ± 36.3NA ± NA5800 ± 35.17150 ± 70.65740 ± 38.76360 ± 50.15680 ± 81.96130 ± 42.0
SecondaryDose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm)

Cmax, norm: Maximum measured concentration of Cytarabine in plasma. The dose normalisation was done by dividing by the dose applied. Unit: nanogram/milliliter/milligram: ((ng/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.

Time frame:
Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.
Reported as:
Geometric mean · (ng/mL)/mg
Dose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm)
(ng/mL)/mgDose Normalized Volasertib+LDAC(Phase I,Schedule A). 150 to 400 mg Volasertib.Dose Normalized Volasertib+LDAC (Schedule A). Phase II. 350 mg Volasertib.Dose Normalized LDAC (Schedule C). Phase II. LDAC Monotherapy.
Dose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm)2.92 ± 61.32.83 ± 52.82.36 ± 77.6
SecondaryDose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours

AUC0-4,norm: Area under the concentration-time curve of Cytarabine in plasma over the time interval from zero extrapolated to 4 hours. The dose normalisation was done by dividing by dose applied. Unit: nanogram\*hour/milliliter/milligram: ((ng\*h/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.

Time frame:
Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h after first drug administration.
Reported as:
Geometric mean · (ng*h/mL)/mg
Dose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours
(ng*h/mL)/mgDose Normalized Volasertib+LDAC(Phase I,Schedule A). 150 to 400 mg Volasertib.Dose Normalized Volasertib+LDAC (Schedule A). Phase II. 350 mg Volasertib.Dose Normalized LDAC (Schedule C). Phase II. LDAC Monotherapy.
Dose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours3.84 ± 30.64.00 ± 35.63.94 ± 43.8
SecondaryAbsolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals

ECG (Electro Cardio Gram) Measurements: Absolute QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) Corrected for Heart Rate Using Fridericia's Formula) Intervals. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.

Time frame:
Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.
Reported as:
Mean · milliseconds (ms)
Absolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals
milliseconds (ms)Phase I+II Volasertib 350 mg+LDACPhase I Schedule B. Volasertib 450 mg
Individual baseline411.6 ± 20.7412.4 ± 18.7
1 hour after start of infusion430.0 ± 20.4441.1 ± 20.0
24 hour after start of infusion414.0 ± 21.3411.9 ± 18.4
SecondaryQTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Change From Baseline at Cycle 1

ECG Measurements: QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) changes from baseline at each time point: The QTcF post baseline measurement obtained at time t minus baseline QTcF measurement. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.

Time frame:
Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.
Reported as:
Mean · millisecond (ms)
QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Change From Baseline at Cycle 1
millisecond (ms)Phase I+II, Volasertib 350 mg+LDACPhase I Schedule B. Volasertib 450 mg
Change from baseline after 1 hour18.5 ± 10.429.6 ± 8.1
Change from baseline after 24 hour1.9 ± 10.5-0.5 ± 9.8
SecondaryPhase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Time frame:
First treatment cycle, up to 28 days.
Reported as:
Count of participants · Participants
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1
ParticipantsPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACTotal Phase I Combined. Schedule A.
Grade 30011215
Grade 423353117
Grade 50003216
SecondaryPhase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Time frame:
First treatment cycle, up to 28 days.
Reported as:
Count of participants · Participants
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1
ParticipantsPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgTotal Phase I Schedule B.
Grade 3501050011
Grade 44134141330
Grade 511002116
SecondaryPhase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Time frame:
From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 615 days.
Reported as:
Count of participants · Participants
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
ParticipantsPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACTotal Phase I Combined. Schedule A.
Grade 31001215
Grade 413553118
Grade 51003217
SecondaryPhase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Time frame:
From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 597 days.
Reported as:
Count of participants · Participants
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
ParticipantsPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgTotal Phase I Schedule B.
Grade 350103009
Grade 44135151332
Grade 521003219
SecondaryPhase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles

Number of patients with AEs following in the in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Time frame:
From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 890 days.
Reported as:
Count of participants · Participants
Phase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
ParticipantsPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDAC
Grade 31312
Grade 41320
Grade 568

Adverse events

Collected over From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase II Schedule C. LDAC45/45 (100%)29/45 (64.4%)43/45 (95.6%)
Phase I Schedule A. Volasertib 150 mg+LDAC4/4 (100%)2/4 (50%)4/4 (100%)
Phase I Schedule A. Volasertib 200 mg+LDAC3/3 (100%)3/3 (100%)3/3 (100%)
Phase I Schedule A. Volasertib 250 mg+LDAC4/5 (80%)3/5 (60%)5/5 (100%)
Phase I Schedule A. Volasertib 300 mg+LDAC9/9 (100%)7/9 (77.8%)9/9 (100%)
Phase I Schedule A. Volasertib 350 mg+LDAC8/8 (100%)6/8 (75%)8/8 (100%)
Phase II Schedule A. Volasertib 350 mg+LDAC38/42 (90.5%)34/42 (81%)41/42 (97.6%)
Phase I Schedule A. Volasertib 400 mg+LDAC3/3 (100%)3/3 (100%)3/3 (100%)
Phase I Schedule B. Volasertib 150 mg11/11 (100%)7/11 (63.6%)11/11 (100%)
Phase I Schedule B. Volasertib 200 mg2/2 (100%)1/2 (50%)2/2 (100%)
Phase I Schedule B. Volasertib 350 mg3/5 (60%)3/5 (60%)5/5 (100%)
Phase I Schedule B. Volasertib 400 mg6/6 (100%)3/6 (50%)6/6 (100%)
Phase I Schedule B. Volasertib 450 mg21/23 (91.3%)16/23 (69.6%)23/23 (100%)
Phase I Schedule B. Volasertib 500 mg5/5 (100%)3/5 (60%)5/5 (100%)
Phase I Schedule B. Volasertib 550 mg4/4 (100%)3/4 (75%)4/4 (100%)
Most frequent serious events
Showing 10 of 132
Most frequent serious events
EventPhase II Schedule C. LDACPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase II Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mg
Febrile neutropeniaBlood and lymphatic system disorders6/452/42/32/52/93/823/422/30/110/20/52/69/232/51/4
C-reactive protein increasedInvestigations0/450/40/33/51/90/80/420/31/110/21/50/60/230/50/4
DiarrhoeaGastrointestinal disorders1/450/40/31/50/90/82/420/30/111/20/50/60/230/50/4
Mucosal inflammationGeneral disorders1/450/40/30/50/90/80/421/31/110/20/51/61/230/52/4
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/450/40/30/51/90/82/420/31/111/20/50/60/230/50/4
PneumoniaInfections and infestations2/450/40/30/51/90/88/420/33/110/20/50/64/232/51/4
ArrhythmiaCardiac disorders0/450/41/30/50/90/80/420/30/110/20/50/60/230/50/4
Myocardial ischaemiaCardiac disorders0/450/41/30/50/90/80/420/30/110/20/50/60/230/50/4
General physical health deteriorationGeneral disorders5/450/41/31/52/91/81/421/31/110/20/50/61/230/50/4
PainGeneral disorders0/450/41/30/50/90/80/420/30/110/20/50/60/230/50/4
Most frequent other events
Showing 10 of 417
Most frequent other events
EventPhase II Schedule C. LDACPhase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase II Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mg
AnaemiaBlood and lymphatic system disorders12/451/42/34/56/93/814/421/34/112/25/54/611/231/52/4
ConstipationGastrointestinal disorders12/450/43/32/52/93/818/420/33/111/20/51/66/231/52/4
FatigueGeneral disorders11/451/41/35/55/94/811/421/33/112/21/50/64/232/52/4
Alanine aminotransferase increasedInvestigations1/450/43/31/50/90/80/420/32/110/20/51/64/231/50/4
C-reactive protein increasedInvestigations5/452/41/32/54/94/82/421/34/112/21/53/67/231/53/4
HyperglycaemiaMetabolism and nutrition disorders2/451/42/34/51/90/80/420/31/112/20/50/61/230/50/4
HypocalcaemiaMetabolism and nutrition disorders1/450/41/33/52/91/82/420/32/112/22/51/66/231/50/4
HypokalaemiaMetabolism and nutrition disorders3/450/41/34/54/96/88/423/32/110/20/50/610/230/52/4
Blood blisterSkin and subcutaneous tissue disorders0/450/40/30/50/91/81/420/31/112/20/51/60/230/50/4
ThrombocytopeniaBlood and lymphatic system disorders8/450/42/34/55/93/89/421/35/111/23/52/612/231/52/4

Baseline characteristics

Treated Set: All patients in Phase I who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason. For the Phase II part, the treated set (Phase II) was defined as all patients in Phase II who received at least a single dose of either Volasertib or LDAC.

Age, Continuous
Age, Continuous(Years)Phase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDACTotal
Mean69.5 ± 12.167.0 ± 3.071.2 ± 6.867.9 ± 12.072.5 ± 6.173.3 ± 7.673.5 ± 3.973.0 ± 4.270.6 ± 2.965.2 ± 20.168.2 ± 7.766.4 ± 7.369.8 ± 4.175.2 ± 5.575.6 ± 4.972.5 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)Phase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDACTotal
Female20233131321613201979
Male2336528124741252396
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I Schedule A. Volasertib 150 mg+LDACPhase I Schedule A. Volasertib 200 mg+LDACPhase I Schedule A. Volasertib 250 mg+LDACPhase I Schedule A. Volasertib 300 mg+LDACPhase I Schedule A. Volasertib 350 mg+LDACPhase I Schedule A. Volasertib 400 mg+LDACPhase I Schedule B. Volasertib 150 mgPhase I Schedule B. Volasertib 200 mgPhase I Schedule B. Volasertib 350 mgPhase I Schedule B. Volasertib 400 mgPhase I Schedule B. Volasertib 450 mgPhase I Schedule B. Volasertib 500 mgPhase I Schedule B. Volasertib 550 mgPhase II Schedule C. LDACPhase II Schedule A. Volasertib 350 mg+LDACTotal
American Indian or Alaska Native0000000000000101
Asian0011000000000114
Native Hawaiian or Other Pacific Islander0000000000000000
Black or African American0000000000000000
White4348831125621543534153
More than one race0000000000000000
Unknown or Not Reported00000000002008717
08

Study locations

27 sites
  • LKH-Univ. Hospital Graz
    Graz, 8036, Austria
  • AZ Sint-Jan Brugge
    Brugge, 8000, Belgium
  • Brussels - UNIV Saint-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Montreal General Hospital - McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
  • CHUS Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • HOP Clémenceau, Hémato, Caen
    Caen, 14033, France
  • HOP, Centre Hospitalier René Dubos, Hémato, Paris
    Cergy Pontoise Cedex, 95303, France
  • HOP Dupuytren 1
    Limoges, 87042, France
  • HOP Edouard Herriot
    Lyon Cedex 03, 69437, France
  • CTR, fondation Paschetta, Hémato, Nice
    Nice Cedex 2, 06189, France
  • HOP Saint-Louis
    Paris cedex 10, 75475, France
  • CTR Henri Becquerel
    Rouen Cedex, 76088, France
  • Campus Virchow-Klinikum, Berlin
    Berlin, 13353, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt/Main, 60590, Germany
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, 24116, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • A.O. Spedali Civili di Brescia
    Brescia, 25123, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Azienda Ospedaliera Policlinico di Modena
    Modena, 41100, Italy
  • Haukeland Universitetssykehus
    Bergen, N-5021, Norway
  • Oslo Universitetssykehus HF, Ullevål sykehus
    Oslo, N-0450, Norway
09

References and documents

Publications

  • Dohner H, Lubbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Muller-Tidow C, Kramer A, Raffoux E, Dohner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8. PubMed 25006120 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Mar 2012, 39 months.

Results were first posted in Oct 2023, 11 years 6 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 39 months is close to that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2008
First posted
Dec 9, 2008
StartActual
Nov 27, 2008
Primary completionActual
Mar 9, 2012
CompletionActual
Apr 23, 2021
Results first posted
Oct 3, 2023
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00804856
Responsible party
Sponsor
First posted
Dec 9, 2008
Start date
Nov 27, 2008
Primary completion
Mar 9, 2012
Completion
Apr 23, 2021
Results posted
Oct 3, 2023
Last update
Oct 3, 2023

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BI 6727 · Cytarabine

Start the discussion